Smartleaf Asset Management’s UroGen Pharma URGN Stock Holding History

Smartleaf Asset Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.6K	Hold	72	–	–	﹤0.01%	2884
2026 Q1	$1.22K	Hold	72	–	–	﹤0.01%	3078
2025 Q4	$1.67K	Hold	72	–	–	﹤0.01%	3037
2025 Q3	$1.38K	Buy	+72	New	+$1.29K	﹤0.01%	2690

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Smartleaf Asset Management's URGN Position: Q2 2026 in Review

Smartleaf Asset Management held its UroGen Pharma (URGN) position steady in Q2 2026 at 72 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2884.

Smartleaf Asset Management first reported a position in URGN in Q3 2025 and has held it in 4 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Smartleaf Asset Management held 72 shares of UroGen Pharma worth $2.6K as of Q2 2026.
Smartleaf Asset Management left its UroGen Pharma share count unchanged in Q2 2026.
UroGen Pharma made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2884 holding.
Smartleaf Asset Management first reported a position in UroGen Pharma in Q3 2025 and has held it in 4 quarters since.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.